Life sciences investor relations
Bridging the science and the street.
Investor relations advisory and support for biotech and medtech companies. Judgment when you need strategy, hands when you need execution.
Working with us
Three steps to a stronger investor story.
-
01
Start with a conversation
Tell Brendan where your investor relations stands today: the story, the shareholder base and the calendar ahead.
-
02
Agree the plan
We set the priorities and choose how to work together: alongside your team, as extra hands, or running the function.
-
03
Face investors with confidence
A clear thesis, the right holders in the room and an IR program that runs on time, quarter after quarter.
24+
years in life sciences investor relations, in-house and agency
Why Deep Cove Insight
The most credible person in your investor conversations should be on your side of the table.
-
Experienced IR leadership
Over 24 years in life sciences investor relations, including in-house and agency roles with Nasdaq-listed companies.
-
Deep industry knowledge
A background in biotech, medtech and capital markets, bridging the gap between science and investors.
-
High-impact execution
Strategic advisory and hands-on support to complement, supplement or fully manage your IR function.
How we work
Three ways to work together.
Every engagement is led by Brendan. The difference is how much of the work you want us to carry.
-
01Complement your team
A senior advisor beside your IR lead: messaging, targeting and board preparation, with experience in the room when it counts.
-
02Supplement your team
Extra hands when the calendar fills: earnings, conferences, roadshows and financings, delivered to your standard.
-
03Fully manage IR
We run the investor relations function for you, from disclosure and earnings to analyst and holder engagement.
Services
Strategy
Authentic Intelligence
Decades of investor relations judgment, sharpened by AI. We give you the wisdom and the agility to act in the present.
- 01
Investor messaging & positioning
We use sector trends and perception audits to build a narrative and investment thesis that institutional investors and sector analysts can repeat.
- 02
Capital markets strategy
A read on market trends, investor sentiment and financing windows, so the company is positioned before it needs capital.
- 03
Buy-side & sell-side targeting & engagement
We identify your peers and the institutions that own them, then attract, engage and keep the right holders, and lay the groundwork for sell-side coverage.
- 04
Data, earnings & financial communications
Press releases, call scripts, Q&A documents and disclosure strategy, drafted and reviewed with you before anything goes out.
- 05
C-suite & board advisory
Market intelligence and investor expectations brought to your executive team and board ahead of the decisions that need them.
Clear, compelling, consistent and compliant.
Execution
Hands-on IR
The day-to-day work of investor relations, done properly, so communication and engagement never stall.
- 06
Presentation & content development
Investor decks, corporate presentations, press releases, IR websites and the rest of your investor materials.
- 07
IR event management
Roadshows, investment conferences and earnings calls, using your full management team, external key opinion leaders (KOLs) and other voices that build credibility.
- 08
ESG & corporate communications
Environmental, social and governance (ESG) reporting, and corporate messaging across media and investor channels.
- 09
Analyst & investor interaction management
Relationships with covering analysts, key shareholders and prospects. We track coverage, ownership and competitors, and run your investor CRM to target non-deal roadshows (NDRs) and conference meetings.
- 10
IR process & infrastructure
The tools, CRM and processes that keep an IR function running, sized to your company rather than to a vendor's pitch.
Shareholder intelligence
Know who moved before your board asks.
Every quarter, institutions disclose their holdings in 13F filings. We turn those filings into a short ownership update for your C‑suite and board.
Top buyers
Who added to their position, and by how much.
The institutions that bought this quarter, ranked by shares added, with the percentage change and whether the position is new. Every row links to the filing it came from.
| Holder | Type | Shares added | Change |
|---|---|---|---|
| Healthcare specialist fund | Active long | +1,240,000 | New |
| Life sciences growth fund | Active long | +860,500 | ▲ 42% |
| Global equity manager | Active long | +512,300 | ▲ 18% |
| Systematic equity fund | Quant | +398,700 | ▲ 65% |
| Broad market index fund | Passive | +276,400 | ▲ 6% |
Source: SEC Form 13F filings. Each holder links to its filing.
Holder mix
See whether specialists are arriving or leaving.
Every holder is tagged by type: healthcare specialist, generalist, quant or index. Three quarters side by side show where your base is moving before it shows up in the stock.
- Healthcare specialist
- Generalist
- Quant
- Index
Exits and largest holders
Who sold out, and who now holds the most.
Full exits are listed separately so they are never lost in a long table. The largest holders as of quarter end close the update, so the board sees the whole base on one page.
- Reviewed by Brendan before it reaches you
- Delivered as an email, a PDF and a private web page
- Healthcare specialist fund9.2%
- Broad market index fund7.1%
- Life sciences growth fund5.8%
- Global equity manager4.4%
- Biotech crossover fund3.7%
- Systematic equity fund2.6%
Full exit Event-driven fund ▼ 100%
Who we work with
Built for the people who face investors.
Chief executives
A clear investment thesis and a story that holds up in every meeting.
Chief financial officers
Earnings, guidance and financing communications that are ready on time.
Boards
A plain read on who owns the company and what investors expect next.
IR leads
Senior support and extra capacity, without adding headcount.
About
Brendan Payne
Deep Cove Insight
Brendan has spent more than 24 years in life sciences investor relations, on both sides of the work: in-house at Nasdaq-listed companies, and at the agencies that serve them.
Clients work with him in three ways: alongside an existing IR team, as extra capacity when the calendar fills, or running the whole function.
